Xiaobing Cui

Xiaobing Cui is a Senior Research Scientist at JURA Bio. Xiaobing has also previously worked as a Senior Scientist at E25Bio, where they designed, expressed, and purified eight innovative enzymes for recombinase polymerase amplification (RPA) - a PCR-based rapid testing technology. Xiaobing also optimized the conditions of RPA and lyophilized the RPA reaction without losing the enzyme activities.

From October 2019 to November 2021, Xiaobing Cui was an Assistant Research Professor at the University of Missouri-Columbia. There, they developed a novel synthetic peptide to treat pulmonary hypertension by targeting response gene to complement 32 (RGC-32). This work led to a US patent (63/066,839). Xiaobing also published 3 research papers in the journals of American Journal of Physiology-Endocrinology and Metabolism and Arteriosclerosis Thrombosis and Vascular Biology. Xiaobing was funded by University of Missouri TRIUMPH grant (5 were selected from 100+ applications). Additionally, they served as ad hoc NIH BMDM study section reviewer and trained junior postdoctoral fellows.

Prior to their work at the University of Missouri-Columbia, Xiaobing Cui was an Assistant Research Scientist at The University of Georgia from August 2011 to October 2019.

Xiaobing Cui completed their Doctor of Medicine (MD) at Peking University. Xiaobing then went on to complete a Doctor of Philosophy (PhD) in Molecular Biology at the same school.

They are on a team with Demi Laforest - Research Assistant, Eli Weinstein - Postdoctoral Researcher, and Kerry Dobbs - Research Scientist I. Xiaobing Cui reports to Cameron Gardner, VP of Research.